Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.

In the Asia-Pacific region, Candida albicans is the predominant Candida species causing invasive candidiasis/candidemia in Australia, Japan, Korea, Hong Kong, Malaysia, Singapore and Thailand whereas C. tropicalis is the most frequently encountered Candida species in Pakistan and India. Invasive isolates of C. albicans, C. parapsilosis complex and C. tropicalis remain highly susceptible to fluconazole (>90% susceptible). Fluconazole resistance (6.8-15%), isolates with the non-wild-type phenotype for itraconazole susceptibility (3.9-10%) and voriconazole (5-17.8%), and echinocandin resistance (2.1-2.2% in anidulafungin and 2.2% in micafungin) among invasive C. glabrata complex isolates are increasing in prevalence. Moreover, not all isolates of C. tropicalis have been shown to be susceptible to fluconazole (nonsusceptible rate, 5.7-11.6% in China) or voriconazole (nonsusceptible rate, 5.7-9.6% in China).

[1]  J. Sobel,et al.  Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J. Sobel,et al.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  F. Fallah,et al.  Candida infection in the intensive care unit: A study of antifungal susceptibility pattern of Candida species in Milad hospital, Tehran, Iran. , 2015, Journal de mycologie medicale.

[4]  M. H. Nguyen,et al.  Clinical perspectives on echinocandin resistance among Candida species , 2015, Current opinion in infectious diseases.

[5]  D. Perlin.  Echinocandin Resistance in Candida. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  A. Chakrabarti,et al.  Incidence and species distribution of candidaemia in Asia: a laboratory-based surveillance study. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[7]  Chang-Pan Liu,et al.  Antimicrobial susceptibility and clinical outcomes of Candida parapsilosis bloodstream infections in a tertiary teaching hospital in Northern Taiwan. , 2015, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[8]  U. Chaudhary,et al.  Changing trends of Candidemia and antifungal susceptibility pattern in a tertiary health care centre. , 2015, Infectious disorders drug targets.

[9]  F. Kong,et al.  Development of fluconazole resistance in a series of Candida parapsilosis isolates from a persistent candidemia patient with prolonged antifungal therapy , 2015, BMC Infectious Diseases.

[10]  J. Turnidge,et al.  Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in Candida spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method , 2015, Antimicrobial Agents and Chemotherapy.

[11]  T. Tan,et al.  Epidemiology of invasive fungal diseases among patients with haematological disorders in the Asia-Pacific: a prospective observational study. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  Chun-Eng Liu,et al.  Changing epidemiology of candidemia in a medical center in middle Taiwan. , 2015, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[13]  B. Posteraro,et al.  Antifungal drug resistance among Candida species: mechanisms and clinical impact , 2015, Mycoses.

[14]  P. Hsueh,et al.  Clinical characteristics and treatment outcomes of patients with candidaemia due to Candida parapsilosis sensu lato species at a medical centre in Taiwan, 2000-12. , 2015, The Journal of antimicrobial chemotherapy.

[15]  Ronald N. Jones,et al.  Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010–2012) , 2015, The Journal of Antibiotics.

[16]  Ying Wang,et al.  Mechanisms of azole resistance in Candida albicans clinical isolates from Shanghai, China. , 2015, Research in microbiology.

[17]  A. Chowdhary,et al.  Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method , 2015, Journal of Clinical Microbiology.

[18]  N. Wijayanti,et al.  Cyclosporine A decreases the fluconazole minimum inhibitory concentration of Candida albicans clinical isolates but not biofilm formation and cell growth. , 2015, Tropical biomedicine.

[19]  Ziyong Sun,et al.  Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. , 2015, The Journal of antimicrobial chemotherapy.

[20]  S. Suh,et al.  Antifungal Susceptibilities of Bloodstream Isolates of Candida Species from Nine Hospitals in Korea: Application of New Antifungal Breakpoints and Relationship to Antifungal Usage , 2015, PloS one.

[21]  Tianming Li,et al.  Genetic and phenotypic characterization of Candida albicans strains isolated from infectious disease patients in Shanghai. , 2015, Journal of medical microbiology.

[22]  B. Kullberg,et al.  Invasive Candidiasis. , 2015, The New England journal of medicine.

[23]  E. Borghi,et al.  Antifungal drug resistance in Candida species. , 2014, Journal of global antimicrobial resistance.

[24]  K. Faksri,et al.  Epidemiology and identification of potential fungal pathogens causing invasive fungal infections in a tertiary care hospital in northeast Thailand. , 2014, Medical mycology.

[25]  D. Perlin.  Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management , 2014, Drugs.

[26]  J. Binongo,et al.  Distribution of Candida species isolated from blood cultures in hospitals in Osaka, Japan. , 2014, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[27]  Parvati Bhat,et al.  Antifungal Susceptibility Patterns, In Vitro Production of Virulence Factors, and Evaluation of Diagnostic Modalities for the Speciation of Pathogenic Candida from Blood Stream Infections and Vulvovaginal Candidiasis , 2014, Journal of pathogens.

[28]  M. Arendrup.  Update on antifungal resistance in Aspergillus and Candida. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[29]  M. Cuenca‐Estrella.  Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[30]  C. Liao,et al.  Antifungal Susceptibilities of Candida Isolates Causing Bloodstream Infections at a Medical Center in Taiwan, 2009-2010 , 2014, Antimicrobial Agents and Chemotherapy.

[31]  J. Perfect,et al.  Predictors and outcomes of Candida bloodstream infection: eight-year surveillance, western Saudi Arabia. , 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[32]  R. Kumar,et al.  Species distribution and drug susceptibility of candida in clinical isolates from a tertiary care centre at Indore. , 2014, Indian journal of medical microbiology.

[33]  T. Ikeda,et al.  Antifungal susceptibility of Candida isolates at one institution. , 2014, Medical mycology journal.

[34]  S. Singh,et al.  Multidrug-resistant endemic clonal strain of Candida auris in India , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[35]  W. Ko,et al.  Changing aetiology of healthcare-associated bloodstream infections at three medical centres in Taiwan, 2000–2011 , 2013, Epidemiology and Infection.

[36]  B. Ko,et al.  Clinical features of patients with infections caused by Candida guilliermondii and Candida fermentati and antifungal susceptibility of the isolates at a medical centre in Taiwan, 2001-10. , 2013, The Journal of antimicrobial chemotherapy.

[37]  I. Balci,et al.  In Vitro Susceptibility of Candida Species to Four Antifungal Agents Assessed by the Reference Broth Microdilution Method , 2013, TheScientificWorldJournal.

[38]  K. Agarwal,et al.  New Clonal Strain of Candida auris, Delhi, India , 2013, Emerging infectious diseases.

[39]  F. Guo,et al.  Invasive candidiasis in intensive care units in China: a multicentre prospective observational study. , 2013, The Journal of antimicrobial chemotherapy.

[40]  C. Pina-Vaz,et al.  Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole for Six Candida Species as Determined by the Colorimetric Sensititre YeastOne Method , 2013, Journal of Clinical Microbiology.

[41]  Yun-Liang Yang,et al.  Species distribution and drug susceptibilities of Candida isolates in TSARY 2010. , 2013, Diagnostic microbiology and infectious disease.

[42]  Beiqin Yu,et al.  Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. , 2013, The Journal of antimicrobial chemotherapy.

[43]  S. Lockhart,et al.  Invasive candidiasis in Pakistan: clinical characteristics, species distribution and antifungal susceptibility. , 2013, Journal of medical microbiology.

[44]  T. Calandra,et al.  ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[45]  Ziyong Sun,et al.  In Vitro Susceptibilities of Yeast Species to Fluconazole and Voriconazole as Determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study , 2012, Journal of Clinical Microbiology.

[46]  M. Pfaller,et al.  Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012 , 2012, Journal of Clinical Microbiology.

[47]  M. Ghannoum,et al.  Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and Candida spp. as Determined by CLSI Broth Microdilution , 2012, Journal of Clinical Microbiology.

[48]  M. Pfaller,et al.  Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. , 2012, The American journal of medicine.

[49]  H. Ibrahim,et al.  In vitro antifungal susceptibilities of Candida isolates from patients with invasive candidiasis in Kuala Lumpur Hospital, Malaysia. , 2011, Journal of medical microbiology.

[50]  Jong-Hee Shin,et al.  First Three Reported Cases of Nosocomial Fungemia Caused by Candida auris , 2011, Journal of Clinical Microbiology.

[51]  Steven D. Brown,et al.  Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[52]  Mina Kim,et al.  Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea. , 2010, Medical mycology.

[53]  Po-Ren Hsueh,et al.  Consensus statement on the management of invasive candidiasis in Intensive Care Units in the Asia-Pacific Region. , 2009, International journal of antimicrobial agents.

[54]  S. Suh,et al.  Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  T. Tan,et al.  A retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore hospitals. , 2008, Annals of the Academy of Medicine, Singapore.

[56]  Steven D. Brown,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Third informational supplement , 2008 .

[57]  Hui Shen,et al.  Fcr1p inhibits development of fluconazole resistance in Candida albicans by abolishing CDR1 induction. , 2007, Biological & pharmaceutical bulletin.

[58]  Yun-Liang Yang,et al.  CaNdt80 Is Involved in Drug Resistance in Candida albicans by Regulating CDR1 , 2004, Antimicrobial Agents and Chemotherapy.

[59]  Pan‐Chyr Yang,et al.  Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole. , 2002, Microbial drug resistance.

[60]  M. Arisawa,et al.  Mechanisms of fluconazole resistance in Candida albicans isolates from Japanese AIDS patients. , 2001, The Journal of antimicrobial chemotherapy.